Version 1.2

Version 1.2

We have updated InRater with a new sleak top design. This should make it more simple to sign in. The next couple of days we will be reordering the frontpage to reflect the activity of our fundmanagers but besides that everything is the same. You will notice a smaller login bar and a link to our facebook and twitter account. …

Read more.

BankNordik - casen udfoldes

BankNordik - casen udfoldes

Banknordik har idag meddelt at man efter indikative bud vælger at gennemføre den før udmeldte afvikling af sine erhvervsaktiviteter. Banken fastholder samtidigt forventningerne til resultatet for 2015 før nedskrivninger, engangsposter, kursreguleringer og skat på 200-220 mio. kr. Det investorerne har ventet på er fastlæggelse af det ekstraordinære udbyttesstørrelse som bliver på 200 millioner DKK i løbet af 2016, udover de allerede …

Read more.

---

DS Torm Q3 og en introduktion til Oaktree-stifter Howard Marks

Danske DS Torm har været en mareridtaktie for aktionærerne. Købte du for 100 kroner for tre år siden, er de 97 forduftet i dag. Er det så ensbetydende med at det også fremover vil være en dårlig investering? Ikke nødvendigvis, for efter sommerens rekonstruktion, hvor en stor del af gælden blev konverteret til aktier, står selskabet i en helt ny …

Read more.

The gateway to small- and midcap stocks in Scandinavia. Steen has more than 15 years hands-on expericence in analysing and investing in stocks. He is a weekly contributor and analyst in “Aktieugebrevet”, one of the leading sources of independent analysis in Denmark.

Peter Hildebrandt, also known as “Akademikeren”, has been investing for more than 17 years. Mainly invests in Undervalued technology and biotech stocks and is currently rotating towards dividend stocks in energy and shipping.

I’m a ten year veteran of biotechnology, and currently pursuing my MBA from UCLA.  I use my knowledge of the industry and business to make my investing decisions.  I look for small to mid-cap biotech companies with innovative research and buy into their company during clinical trials.

Andreas is providing stock tips with deep fundamental research behind each stock he recommends. He is privately a portfolio manager at his own Investment company where he Invest in stocks, options, CFD’s etc. with a balanced long/short approach.

Jacob’s approach is to search for that which is undervalued and where the discount to the intrinsic value provides a large margin of safety. He believes sectors that are either out of favor or in distress typically offer the best opportunities.